Cagrilintide Dosage Chart 2026 — CagriSema Trial Data Overview

Medical Disclaimer

This website is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or supplement. Dosage information reflects published FDA-approved labeling or publicly available clinical trial data — individual treatment decisions must be made by a licensed physician.

About cagrilintide

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, most notably studied in combination with semaglutide (CagriSema). It is not yet FDA-approved. This page summarizes clinical trial dosing data for informational reference.

Indication

Investigational. Data from Phase 2/3 clinical trials. Not for clinical use.

Research / Trial Dosing Reference

Dosing data from published clinical trials. Not an approved prescription protocol.

Week / Phase	Dose	At 2.5 mg/mL	At 5 mg/mL	Notes
Weeks 1–4 (trial)	0.3 mg	3 units (1 mg/mL)	—	Starting dose in trial protocol.
Weeks 5–8 (trial)	0.6 mg	6 units (1 mg/mL)	—	Escalation step.
Weeks 9–12 (trial)	1.2 mg	12 units (1 mg/mL)	—	Higher dose arm.
Maintenance (trial)	2.4 mg	24 units (1 mg/mL)	—	CagriSema combination used 2.4 mg cagrilintide + 2.4 mg semaglutide. Showed ~25% weight loss.

Units shown assume a standard U-100 insulin syringe (100 units = 1 mL). Always confirm your vial concentration with your pharmacy.

Dose Calculator

Enter your prescribed dose and vial concentration to calculate how many units to draw.

mg ↔ Units Dose Calculator

Convert between milligrams and insulin-syringe units for compounded GLP-1 medications. Uses a standard U-100 syringe (100 units = 1 mL).

Medication

Vial Concentration (mg/mL)

Dose (mg)

Units (U-100 syringe)100 units

Volume1.000 mL

2.5 mg at 2.5 mg/mL → 1.000 mL → 100 units on a U-100 (100-unit / 1 mL) insulin syringe

Always verify calculations with your prescribing provider or pharmacist before administering any medication. This calculator is for reference only.

Injection Sites

Abdomen (trial protocol)

Subcutaneous injection, same sites as other GLP-1 agents.

Rotate sites
In CagriSema trials, cagrilintide and semaglutide were given as separate injections

Storage Instructions

Investigational product
If compounded: follow compounding pharmacy instructions
Requires refrigeration (2°C–8°C) typically

Common Side Effects

Contact your healthcare provider if side effects are severe or persistent.

Nausea
Vomiting
Injection site reactions
Decreased appetite
When combined with semaglutide: amplified GI side effects

Frequently Asked Questions

What is cagrilintide?

Cagrilintide is a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin that suppresses appetite and slows gastric emptying. Cagrilintide extends this effect with a once-weekly injection. Novo Nordisk is studying it primarily in combination with semaglutide.

What is CagriSema?

CagriSema is the co-formulation of cagrilintide and semaglutide being developed by Novo Nordisk. Phase 3 trials (REDEFINE program) are ongoing. It achieved ~25% average weight loss in Phase 2, which would be competitive with retatrutide and tirzepatide.

Is cagrilintide available as a compounded peptide?

Some peptide research vendors offer cagrilintide, but it is not FDA-approved and its safety and quality outside clinical trials is unverified. Consult a physician before considering any experimental compound.